ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction

Zhang, Sainan; Li, Mengyue; Tan, Yilong; Zhang, Juxuan; Liu, Yixin; Jiang, Wenbin; Li, Xin; Qi, Haitao; Tang, Lefan; Ji, Ran; Zhao, Wenyuan; Gu, Yunyan*; Qi, Lishuang*哈尔滨医科大学
Journal of Molecular Medicine2022-12DOI: 10.1007/s00109-022-02266-4
17阅读
引用收藏
分享

摘要

There is no robust genomic signature to predict the prognosis of patients with early-stage lung adenocarcinoma (LUAD). It was known that clonal heterogeneity was closely associated to tumour progression and prognosis prediction. Herein, using stage I patients from The Cancer Genome Atlas, we identified the clonal/subclonal events of each gene and preselected a set of genes with prognosis-specific mutation patterns based on a robust published transcriptomic prognostic signature. Subsequently, we constructed a mutational prognostic signature (MPS), whose prognostic performance was independently validated in two datasets of stage I samples. The predicted high-risk patients had significantly higher immune cell infiltration, along with higher expression of cytotoxic and immune checkpoint genes, and an integrated dataset with 88 samples confirmed that high-risk patients could benefit from immunotherapy. The developed MPS can identify the high-risk patients with stage I LUAD and improve individualised treatment planning of high-risk patients who might benefit from immunotherapy. Key messages We creatively developed a prognostic signature (57-MPS) based on clonal diversity. The high-risk samples displayed an underlying immunosuppressive mechanism. 57-MPS improved the predictive performance of PD-L1 for immunotherapy.

学科与关键词

关键词
Lung adenocarcinomaPrognosisSubclonal mutationSignatureImmunotherapy
相关
加载中…
  • Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu, Chengde; Rao, Xiang; Lin, WeiCancer Med, 2021, 10(3): 806-823.
  • Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
  • Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
    Li, Na; Wang, Jiahong; Zhan, Xianquan*Frontiers in Immunology, 2021, 12: 752643.被引 19
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Molecular Medicine
发表日期
2022-12
卷期
第 100 卷, 第 12 期
页码
1755-1769
DOI
10.1007/s00109-022-02266-4
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81872396, 32270710]; HMU Marshal Initiative Funding [HMUMIF-21023]; Postdoctoral Scientific Research Developmental Fund [LBH-Q16166]

作者

  • Z

    Zhang, Sainan (第一作者)

    harbin med univ

  • L

    Li, Mengyue

    harbin med univ

查看全部 13 位作者收起作者
  • T

    Tan, Yilong

    harbin med univ

  • Z

    Zhang, Juxuan

    harbin med univ

  • L

    Liu, Yixin

    harbin med univ

  • J

    Jiang, Wenbin

    harbin med univ

  • L

    Li, Xin

    harbin med univ

  • Q

    Qi, Haitao

    harbin med univ

  • T

    Tang, Lefan

    harbin med univ

  • J

    Ji, Ran

  • Z

    Zhao, Wenyuan

    harbin med univ

  • G

    Gu, Yunyan (通讯)

    harbin med univ

  • Q

    Qi, Lishuang (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417